Advice Pool - Health and Fitness

Dementia is defined as a progressive loss of memory and mental capacity that is usually experienced by people as they get older, though there isn't any predetermine

According to USFDA, a combination product is one composed of any combination of a drug and device; biological product and device; drug and biological product

d age in which such a condition can strike. Dementia is a slow, progressive disease process that can exhibit signs and symptoms for months, or even years. Of all th

; or drug, device, and biological product and fixed dose combination would include two or more combinations of drug.

Examples of combination products may in

e types of dementia, Alzheimer's disease is by far the most prevalent. Almost 70% of dementia cases are diagnosed as Alzheimer's disease, and the word has spread fa

lude drug-coated devices, drugs packaged with delivery devices in medical kits, and drugs and devices packaged separately but intended to be used together.

r and wide with its alarming, irreversible and dehabilitating consequences.

Alzheimer's is a degenerative disease that affects the brain and results in gradual mem

here is enormous increase in the number of combination products entering the market in the recent years. Combination products have proven advantages but fixe

ory loss of both long-term and short-term memory capabilities, as well as personality change and impaired ability to reason and think. It isn't difficult for a phys

d dose combinations are still in the process of convincing regulatory authority on their advantages over the single ingredient formulations.

Combination pro

ician to diagnose dementia, and several tests will help determine whether or not you or a loved one might be experiencing early stage Alzheimer's. The disease affec

ucts have become life saving products for the pharmaceutical companies who doesn’t have many innovative molecules in their product pipeline and have been inc

ts people differently, as well as their life expectancy after diagnosis. Some people decline rapidly while others don't. Some people live only a few years after dia

easingly used in the product life cycle management. Even the companies having product patents are trying to extend their product life cycle through the combi

gnosis, while others live twenty or more years with the disease. Today, roughly four million people have been diagnosed with Alzheimer's in the United States alone.

nation products and maximize the revenues. But the companies involved in this practice are overlooking that they are burdening the patients both economically

It is most common in people over 65 years of age, though people in their forties and fifties have been diagnosed with it as well. For about 10% of those diagnosed

and physically. They need to rightly judge the benefits of the combination products and they have to even look at the risks involved when combining the produ

with early onset Alzheimer's in their forties and fifties, there is a family history of the disease present.

While much progress has been made to understand what A

ts. Some of the combination products were well accepted by physicians while others suffered. Companies involved in development of combination products are fi

lzheimer's disease is and how it affects the human body, it isn't yet exactly clear what causes it, nor has a drug been developed that will cure it. It's well under

ding difficulty in defining their combination products and facing various challenges from selecting a combination to marketing it.

Following aspects would a

stood that a combination of brain cell death and a lack of a neurotransmitter called acetylcholine causes symptoms of Alzheimer's.

People these days are desperate

dd to the challenges in developing combination products:

Which markets to tap where the combination products can do fairly well?
Which combination prod

to find a way to prevent or slow the onslaught of Alzheimer's, but studies are slow to show progress. Some recent studies tend to show that daily doses of a nonster

cts are meaningful and rational?
Which therapeutic categories to select?
Which Combinations can address unmet needs of the patients?
Do combin

oid anti-inflammatory drug may reduce chances of being stricken with the disease, but results are non-definitive to date. One thing is certain, however, despite com

tions increase the patient compliance?
What would be the developing cost?
How to tackle the risks encountered during combination product developmen

mon rumor, and to the contrary, Prempro or Premarin hormone therapy does not prevent the disease. Another common rumor is that the herb ginkgo may help to reduce th

t?

As combination products don't fit into the traditional categories of drugs, medical devices, or biological products, the USFDA is in the process of devel

e chance of succumbing to the disease, but again, results aren't definitive.

People diagnosed with Alzheimer's disease are encouraged by doctors to remain as activ

ping new procedures for reviewing their safety, efficacy and quality.

Professional from academic institutions, pharmaceutical industries, health care indust

e as possible in order to help prevent a rapid decline of mental acuity. Social interaction, stimulation and regular forms of exercise will help keep brain cells ac

y and representatives from various regulatory agencies are working out to design the regulatory requirements for manufacture and sale of combination products

tive. Maintaining a schedule may help patients maintain cognitive levels longer, as well as the creation of notes or small signs throughout the home to help with vi

.

As there is an increasing trend of the combination products companies manufacturing such products should be able to tackle the problems involved in the de

sual-cognitive functions.

The diagnosis of Alzheimer's in a loved one is a terrible blow. There are no easy answers on how to deal with the disease. Information is

elopment. They need to be wiser in analyzing the market trends and the regulatory requirements.

Companies that provide selfless information through particip

knowledge, however, and the more we know about the how's and whys of the disease, the better equipped we will be to help care for those diagnosed with Alzheimer's.

tion in industry events and feedback to regulatory authorities would be able to face the challenges and will be successful in developing combination products

HTTP = HTML link (for blogs, profiles,phorums):
<a href="http://www.advicepool.org.ua/article/241913/advicepool-Facts-About-Alzheimers.html">Facts About Alzheimer's</a>

BB link (for phorums):
[url=http://www.advicepool.org.ua/article/241913/advicepool-Facts-About-Alzheimers.html]Facts About Alzheimer's[/url]

Confidence and conviction during your call to action is a critical persuasive component. The effectiveness of your call to action is all about how the audience perceives you. Because it is such a crucial component, I would suggest that you write your call to action before beginning any other phase of your presentation. When doing so, ask yourself what exactly it is you want your audience to do upon completion of your presentation and then build your presentation around the answer.

Endowment policies can fetch thousands on the open market and selling endowment policies is big business but do you understand the ins and outs?

Sometimes it’s hard to see the forest from the trees. Sometimes its hard to see how much you can bring your self down.

Tags

Links

Advice Pool - Facts About Alzheimer's

Related Articles: